KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EBIT (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBIT for 6 consecutive years, with -$50.1 million as the latest value for Q3 2023.

  • On a quarterly basis, EBIT rose 11.88% to -$50.1 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$217.2 million, a 7.5% increase, with the full-year FY2025 number at -$136.3 million, up 38.3% from a year prior.
  • EBIT was -$50.1 million for Q3 2023 at Twist Bioscience, up from -$60.8 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$24.0 million in Q3 2020 to a low of -$61.6 million in Q1 2023.
  • A 5-year average of -$43.7 million and a median of -$42.1 million in 2021 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 367.62% in 2019, then surged 41.26% in 2020.
  • Twist Bioscience's EBIT stood at -$55.8 million in 2019, then soared by 41.26% to -$32.8 million in 2020, then tumbled by 70.59% to -$55.9 million in 2021, then grew by 20.22% to -$44.6 million in 2022, then fell by 12.28% to -$50.1 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's EBIT are -$50.1 million (Q3 2023), -$60.8 million (Q2 2023), and -$61.6 million (Q1 2023).